Background TDP-43 is a major component of the ubiquitinated inclusions that characterise amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) with ubiquitin inclusions (FTLD-U). TDP-43 is an RNA-binding and DNA-binding protein that has many functions and is encoded by the TAR DNA-binding protein gene (TARDBP) on chromosome 1. Our aim was to investigate whether TARDBP is a candidate disease gene for familial ALS that is not associated with mutations in superoxide dismutase 1 (SOD1).
Introduction
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterised by relentless degeneration of upper and lower motor neurons; this leads to progressive weakness and eventually death within 3-5 years. 1 Most cases are sporadic, but about 10% are familial. 1 Familial ALS is genetically heterogeneous: about 20% of cases are accounted for by mutations in Cu/Zn superoxide dismutase 1 (SOD1), which predominantly cause autosomal-dominant disease, 2 but other genes are mutated in rarer forms of ALS. These genes include senataxin (SETX), a DNA/RNA helicase that causes juvenile ALS, 3 alsin (ALS2), 4, 5 dynactin (DCTN1), 6, 7 angiogenin (ANG), 8 and synaptobrevin-associated membrane protein B (VAPB). 9 The causes of sporadic ALS, which accounts for more than 90% of ALS cases, have been more diffi cult to identify genetically.
Mutations in a locus on chromosome 9p21, for which the gene has not yet been identifi ed, are responsible for a form of ALS with frontotemporal lobar degeneration (FTLD). [10] [11] [12] FTLD, a group of neurodegenerative disorders in which there is behavioural dysfunction, language dysfunction, or both, is thought to be the most common non-motor defi cit in patients with ALS. [12] [13] [14] There is accumulating evidence that frontal lobe dysfunction is present in up to 50% of patients with ALS, with as many as 20% showing abnormalities that meet Neary criteria for clinical FTLD. [15] [16] [17] This clinical overlap between ALS and FTLD is particularly interesting because both ALS and the most common FTLD subtype, FTLD with ubiquitin inclusions (FTLD-U), are characterised by ubiquitin-positive, taunegative, and α-synuclein-negative cytoplasmic inclusions in CNS neurons and glia. The major disease protein in both ALS and FTLD-U inclusions is the ubiquitinated TAR DNA-binding protein 43 (TDP-43). 18, 19 TDP-43 pathology is not found in SOD1-associated familial ALS, suggesting that mechanistically ALS is heterogeneous. 20 TDP-43 is a 414-amino-acid nuclear protein encoded by TARDBP on chromosome 1p36.2. It was originally identifi ed as a transcriptional repressor that binds to the TAR-DNA element of HIV and, because of its molecular weight of 43 kDa, it was named TDP-43. 21 TDP-43 is involved in regulation of gene expression and splicing, and is part of a complex that splices the cystic fi brosis transmembrane conductance regulator gene (CFTR). [22] [23] [24] The TDP-43 inclusions in ALS and FTLD-U put these two disorders in a class of neurodegenerative diseases where abnormal protein aggregation occurs. 25 Such disorders include Alzheimer's disease, Parkinson's disease, prion disorders, tauopathies, trinucleotide repeat disorders, and other rare brain amyloidoses. In all of these disorders, dominant mutations in the gene that encodes the deposited protein account for at least some cases of the disease. For example, mutations in the amyloid precursor protein gene APP, which encodes the Aβ peptide found in amyloid plaques in Alzheimer's disease, are a rare cause of this disease. 25 Likewise, mutations in the gene that encodes α-synuclein (SNCA), the major protein component of Lewy body deposits in Parkinson's disease, are a rare cause of this disease. 25 Mutations in MAPT, which encodes tau, the protein component of neurofi brillary tangles, cause some cases of frontotemporal dementia without ubiquinated TDP-43 deposits. 26 TARDBP is thus an obvious candidate gene for familial ALS and other familial frontotemporal dementia syndromes not caused by mutations in MAPT or progranulin. That several mutations in TARDBP were identifi ed in ALS while this manuscript was in preparation is not surprising, although the previous studies 27, 28 do not report an association with neuropathology. The mutations in these studies all cluster in exon 6 of TARDBP; two (Ala315Thr and Met337Val) segregate with disease in two familial ALS kindreds and two (Gln331Lys and Gly294Ala) were identifi ed in patients with sporadic ALS. However, two other studies found no TARDBP mutations in 214 patients with FTLD, 29 173 patients with FTLD, 30 or 237 patients with sporadic ALS. 30 Furthermore, no genetic association was seen between TARDBP polymorphic sites and FTLD or ALS, [29] [30] [31] although there was a non-signifi cant association with two singlenucleotide polymorphisms in patients with ALS and frontotemporal dementia in one study. 31 Our aim was to further defi ne the spectrum of TARDBP mutations by DNA sequence analysis of patients with ALS, FTLD, or both.
Methods

Participants
TARDBP was screened for mutations in patients with a clinical diagnosis of ALS or ALS with FTLD, and in autopsies of patients who had confi rmed TDP-43 pathology and a neuropathological diagnosis of ALS, FTLD-U, or FTLD with motor neuron disease ( To assess pathogenicity, we tested for TARDBP variants in relatives of two individuals who had these variants. We also tested control samples from people who were of a similar age and the same ethnic origin as these two families. Control samples were from neurologically healthy control participants from the Coriell Institute (Camden, NJ, USA), the University of Washington, and the National Taiwan University, and from patients at the Alzheimer Disease Center at the University of Pennsylvania. Control brain autopsy samples without evidence of neurodegenerative diseases were obtained from the University of Pennsylvania. All samples were collected with approval of the relevant institutional review boards and informed consent was obtained from all 
Value (n=259)
Procedures and analysis
Where possible, genomic DNA was extracted from blood (patients) or CNS tissue (autopsies) by standard methods (Qiagen, Valencia, CA, USA). For one sample, DNA was obtained from non-CNS paraffi n-embedded tissue, also with Qiagen reagents. The entire coding region of TARDBP, consisting of exons 2-5, the fi rst 531 nucleotides of exon 6, and an average of 100 nucleotides of fl anking 3Ľ and 5Ľ intronic regions of each exon, were fully sequenced in both directions. Variants identifi ed were confi rmed with repeat sequencing of new amplicons. Primers used to amplify part or all of each exon were selected with Primer3 software (Whitehead Institute, MA, USA) and primer sequences are available from the corresponding author on request.
At the University of Pennsylvania, amplifi cation reactions (50 μL) were done with 200 ng DNA, AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA), and 0·8 μM (fi nal concentration) of each primer. The amplifi cation protocol consisted of the following steps: incubation at 95°C (10 min); 14 cycles of 95°C (30 s), 60°C (30 s) with a reduction of 0·5°C per cycle (exons 4-6) or 58°C with a reduction of 0·5°C per cycle (exons 2 and 3), and 72°C (1 min); 20 cycles of 95°C (30 s), 53°C (30 s), and 72°C (1 min); and a fi nal 72°C extension (5 min). Amplifi cation products were purifi ed with AMPure (Agencourt Bioscience, Beverly, MA, USA) followed by single pass bidirectional sequencing by Agencourt Bioscience or with a CEQ8000 (Beckman Coulter, Fullerton, CA, USA) with Beckman Coulter sequencing reagents. Results were analysed using Mutation Surveyor software (SoftGenetics, PA, USA).
At the University of Washington and Center for Neuropathology and Prion Research, amplifi cation reactions of 50 ng genomic DNA included 20 pmol primers and 10 μL HotStarTaq DNA polymerase master mixture (Qiagen, Valencia, CA, USA) in a fi nal volume of 20 μL. Amplifi cation conditions were as follows: 1 cycle of 95°C (15 min); 32 cycles of 98°C (20 s), 60°C (30 s), and 72°C (2 min); and a fi nal 5 min extension at 72°C. On completion of amplifi cation, 1 μL of ExoSAP-IT (USB Corp, Cleveland, OH, USA) was added to the PCR products and digested overnight at 37°C to remove the residual primers and deoxynucleoside triphosphates. ExoSAP-treated PCR products (4 μL) were sequenced (30 cycles) with the BigDye terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) in a fi nal volume of 10 μL. The sequence data were collected and analysed on a 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), and nucleotide variants were detected by sequence alignment using SEQUENCHER software (Gene Codes Corp, Ann Arbor, MI, USA).
We genotyped control samples for TARDBP variants NM_007375 869G→C (Gly290Ala) and 892G→A (Gly298Ser) with a TaqMan chemistry-based allelic discrimination assay, with Assay by Design probes (Applied Biosystems, Foster City, CA, USA) and an Applied Biosystems 7900 PCR system, followed by analysis with Sequence Detection System 2.2.1 software (Applied Biosystems). The DNA samples with the variants identifi ed by DNA sequencing served as positive controls for each assay. An upper confi dence boundary (p) of a mutation frequency when none are observed in a control population was calculated as (1-p) N =α where N is the number of chromosomes tested and α is the signifi cance.
Post-mortem and standard neuropathological assessment included histological staining with Luxol fast blue, periodic acid Schiff , and haematoxylin and eosin. Immunostaining for TDP-43 (anti-TDP-43 rabbit polyclonal antibody, Protein Science, Chicago, IL, USA; 1:2000) and α-synuclein (LB509, 1:200) were done as described previously.
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Role of the funding source
The study sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The corresponding author had full access to all data in this study and had the fi nal responsibility for the decision to submit for publication.
Results
TARDBP was screened for mutations in 148 patients with clinical ALS without FTLD, 20 patients with clinical ALS and FTLD, autopsies from 44 patients who had confi rmed TDP-43 pathology and a neuropathological diagnosis of ALS, and autopsies from 47 patients who had confi rmed TDP-43 pathology and either FTLD-U or FTLD plus motor neuron disease. Table 1 shows the characteristics of patients.
Control samples were obtained from 276 neurologically healthy white individuals at the Coriell Institute, from 381 neurologically healthy white individuals (mean age 76 years) at the University of Washington, from 48 white clinical controls (mean age 76 years) at the Alzheimer Disease Center at the University of Pennsylvania, and as 42 brain autopsy samples without evidence of neurodegenerative diseases (mean age 69 years) from the University of Pennsylvania. Samples from 380 Chinese control participants (mean age 72) were obtained from National Taiwan University.
We identifi ed two heterozygous missense variants, NM_ 007375: 869G→C (Gly290Ala) and 892G→A (Gly298Ser), in exon 6 of TARDBP in two families with apparent autosomal-dominant familial ALS (fi gure 1). Family ND654, in which the 869G→C mutation was detected, is white (maternal side of Polish ancestry and paternal side of Austrian and Ukrainian heritage); family QBB, in which the 892G→A mutation was detected, is Chinese. Neither mutation was detected in samples from the 747 elderly white controls (95% upper confi dence limit 0·002). The
For Primer3 see http://primer3. sourceforge.net 892G→A mutation was not found in the 380 elderly Chinese controls (95% upper confi dence limit 0·004); these controls were not screened for 869G→C.
The two aff ected members of family ND654 had the Gly290Ala mutation; clinical characteristics of these individuals are summarised in table 2. The proband in family ND654 (III:4, fi gure 1A) presented with dysarthria and dysphagia at 51 years of age and was diagnosed with ALS 8 months after the onset of symptoms. In the 13 months after diagnosis, she rapidly developed limb weakness, became anarthric, required a feeding tube and non-invasive ventilatory support, and subsequently died in hospice care. An autopsy was not done. Her father (II: 14) presented with arm weakness at 47 years of age before rapid progression to death 16 months after onset with a clinical diagnosis of ALS. An autopsy showed degeneration of cells in the anterior horn of the spinal cord, most prominently in the cervical cord, consistent with ALS. At the time of this genetic analysis, CNS tissue was not available for the father of III:4 (the autopsy of II:14 had been done about 40 years previously), but DNA testing of non-CNS paraffi n-embedded tissue confi rmed the presence of the Gly290Ala mutation in the father; the unaff ected mother (II:15) did not have the mutation. No other aff ected or unaff ected older individuals were available. The siblings (III:1-3), who are similar in age to the proband, have not been clinically assessed but are alive and well.
In the QBB family, there are fi ve cases of rapidly progressive ALS in two generations (fi gure 1). Clinical characteristics for all fi ve patients are summarised in table 2; detailed clinical information was available for three of these family members. Disease onset consisted of weakness of the left hand in III:4, weakness of the right leg in II:7, and dysarthria in II:2. Electrophysiological studies in these patients were consistent with ALS. In all instances, the disease rapidly progressed to quadraparesis and compromised respiratory function. The Gly298Ser mutation was present in all three aff ected individuals (II:2, II:7, and III:4) with available DNA but was absent in two unaff ected individuals (II:6 and III:8). This mutation was also absent in II:4 (the mother of proband III:4), thus making the father (II:3) an obligate carrier. Individual III:1 died at 51 years of age and by report of the family was said to have ALS. CNS autopsies were done for QBB family members II:5, II:7, and III:4 and all three had neuropathological changes consistent with a diagnosis of ALS, including neuronal loss, gliosis, and Bunina bodies in the anterior horns of the spinal cord and pallor of the corticospinal tracts. CNS tissues from II:7 and III:4 were available for further analyses and Betz cell loss was seen in the primary motor cortex of both patients (fi gure 2). Sections of medulla revealed pallor of the pyramidal tracts, but only patient III:4 showed loss of hypoglossal neurons. Immunohistochemistry revealed the presence of TDP-43 inclusions in upper and lower motor neurons and elsewhere in the CNS of both patients (fi gure 3). 18, 32 Immunostaining revealed fi lamentous and round inclusions immunopositive for TDP-43 in anterior horn cells of the QBB family members II:7 and III:4 (fi gure 2A-C). We also saw abundant diff use granular cytoplasmic staining with nuclear clearing of remaining motor neurons in these patients; we referred to these fi ndings as pre-inclusions. Pre-inclusions were also seen in the hypoglossal nuclei of both family members (fi gure 3D). The round inclusions in II:7 were not stained with haematoxylin and eosin or with antibodies to α-synuclein. TDP-43-immunopositive neuronal and neuritic inclusions, pre-inclusions, and glial inclusions also were seen in diverse distributions and frequencies in the substantia nigra (III:4, fi gures 2D and 3E), dentate gyrus of the hippocampus (III:4, fi gure 3A), cingulate gyrus (II:7, fi gure 2E), frontal cortex (III:4), amygdala (III:4 and II:7, fi gures 2F and 3F), and frontal and temporal cortices (III:4 and II:7, fi gure 3B, C). Overall, both patients had more TDP-43-positive preinclusions than did other patients with sporadic ALS. α-Synuclein immunostaining of the spinal cord, medulla, substantia nigra, and amygdala was negative for neuronal lesions but positive for gliosis in spinal cord anterior horns. 33 We did not detect SOD1-positive inclusions in III:4 and II:7.
Discussion
We report here the identifi cation of two novel genetic variants in the C-terminal region of TARDBP, which encodes the glycine-rich domain of TDP-43. We provide evidence that these variants have a pathogenic role in ALS and we show in autopsy results a direct link between presence of a TARDBP mutation with TDP-43 pathology and autosomal-dominant ALS. This fi nding further implicates TDP-43 as an active participant rather than an innocent bystander in TDP-43 proteinopathies-a class of neurodegenerative disorders that includes ALS and FTLD-U.
These mutations we identifi ed were absent in controls and segregated with disease in the two pedigrees described. Abnormal aggregated TDP-43 was present in the two members of the QBB family who had the Gly298Ser mutation for whom autopsy samples were available. The family data and pathological evidence support a pathogenic role more strongly for Gly298Ser than for the Gly290Ala variant, but identifi cation of the similar and nearby Gly290Ala mutation in family ND654 supports its pathogenic association with familial ALS. These mutations are also both in the same exon 6 region as are previously identifi ed TARDBP mutations, particularly the Gly294Ala mutation, which further supports their pathogenicity. 27, 28 Although not all genes that have been implicated in ALS and frontotemporal dementia were screened in our samples, the evidence provided here and elsewhere 27, 28 shows that the Gly298Ser and Gly290Ala variants are mutations that are pathogenic in ALS.
How might these TARDBP variants cause disease? TDP-43 is a ubiquitously expressed, highly conserved protein with several functional domains. These domains include a nuclear localisation signal (amino acids [aa] 82-98), two RNA-recognition motifs (RRM1 [roughly aa 106-175] and RRM2 [roughly aa 191-262]), and a C-terminal glycine-rich domain (roughly aa 274-413). This glycine-rich domain, in which both of our mutations are found, regulates the alternative splicing of several genes, including CFTR, 22, 34 which is altered in cystic fi brosis, and the apolipoprotein IIa gene. 35 The C-terminal domain also functions as a transcriptional repressor and regulates tissue-specifi c expression of the mouse testisspecifi c SP-10 gene. 36 Finally, the glycine-rich C-terminal domain binds several heterogeneous nuclear ribonucleoproteins involved in the biogenesis of messenger RNA. 37, 38 Thus, although the physiological functions of TDP-43 are incompletely characterised, TDP-43, and in particular the C-terminal domain, function in the regulation of gene expression. 34 That both the Gly298Ser and Gly290Ala mutations identifi ed here, and the Gly294Ala TARDBP mutation reported previously, 27, 28 involve glycine residues within ten amino acids of each other in the C-terminal domain of TDP-43 suggests that all three mutations cause disease through similar mechanisms. Specifi cally, we propose that these mutations alter the normal functioning of this domain in regulation of gene expression.
The TARDBP mutations reported here occurred in about 1% (2/188) of patients who had ALS without dementia and in less than 1% (2/259) of all patients we tested, but this is not unprecedented because mutations in SNCA are a rare cause of familial Parkinson's disease. However, only 15% of the people we studied had familial ALS without dementia (table 1) ; thus, mutations were identifi ed in 5% (2/39) of patients with familial ALS but no dementia and in 3% (2/65) of patients with familial ALS who were tested, including those with FTLD-U. This percentage is similar to the results of Gitcho and colleagues, 27 who identifi ed Ala315Thr in about 3% of participants with familial ALS, FTLD with motor neuron disease, or FTLD-U. However, this proportion is higher than the rate reported by Sreedharan and colleagues, 28 who identifi ed TARDBP mutations in 1 of 154 participants with familial ALS and 2 of 372 participants with sporadic ALS.
In addition to linking variations in TARDBP to clinical familial ALS, we have shown the presence of TDP-43 neuropathology in aff ected family members who have the TARDBP mutations. Specifi cally, patients with the Gly298Ser mutation in TARDBP had TDP-43-positive inclusions in many areas of the CNS, including remaining anterior horn cells in diseased spinal cord. Our fi nding that pre-inclusions were more common in patients with ALS who had TARDP mutations than in those who did not might refl ect a unique characteristic pattern of neuropathology for the Gly298Ser and Gly290Ala mutations of TARDBP, although analysis of further patients will be needed to confi rm this suggestion.
The identifi cation of three separate mutations in TARDBP associated with familial ALS, with confi rmed TDP-43 positive pathology in at least one kindred that had these mutations, provides direct links between a TDP-43 amino acid change, TDP-43 neuropathology, and ALS neurodegeneration. Further studies will help in elucidation of the pathological mechanisms that underlie diseases characterised by TDP-43 proteinopathy, such as ALS and FTLD-U.
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